South Africa Protests Urge US and EU to Move Forward on TRIPS Waiver for COVID-19 Vaccines and Medical Tools

The landmark TRIPS waiver proposal was originallyput forward by India and South Africa one year agoand is now officially backed by 64 sponsoring governments, with more than 100 countries supporting overall. However, despite dozens of statements by supporting governments emphasizing the waiver’surgency and importance, the proposal has been effectively stalled by a small number of opposing governments, including many in the European Union—primarily Belgium, Denmark, Finland, Germany, Ireland, the Netherlands, and Sweden—plus Norway, Switzerland, and the UK. “We have gathered outside the embassies of Belgium and the Netherlands to relay a clear message to EU countries to stop stonewalling this critical waiver and stop putting multinational pharmaceutical corporation profiteering over human lives,” said Candice Sehoma, South Africa advocacy officer for MSF’s Access Campaign. “Even though France, Greece, Italy, and Spain have already come out in support of the waiver, another handful of governments in the EU with strong ties to pharmaceutical corporations is choosing to put shareholder interests over the lives of people across the globe. We are calling on supportive EU countries to show real leadership and convince their neighbors to do the right thing so that the EU as a whole finally gets in line and supports the TRIPS waiver.” The world continues to witness global inequity in access to COVID-19 medical tools with high-income countries like the US stockpiling and hoarding treatments and vaccines instead of allowing the fair distribution needed to end this pandemic. The US recently reserved1.7 million treatmentsof the promising COVID-19 treatmentmolnupiravir, which, if approved, could be critical for reducing hospitalizations and deaths. The molnupiravir case illustrates why the TRIPS waiver is so desperately needed; while the US government funded the development of the medicine by Emory University, pharmaceutical corporations Ridgeback and Merck obtained the licensing and rights for the medicine. Instead of offering licenses widely to all competent manufacturers in different countries, avoluntary license signed in April 2021only includes Indian generic companies and hinders countries like Brazil from being able to produce and import the API (raw material) and generic versions. “We have been saying from the start of this pandemic that governments cannot rely on voluntary measures by pharmaceutical corporations, and the molnupiravir example is a case in point,” said Felipe Carvalho, MSF Access Campaign coordinator in Brazil. “We cannot welcome a voluntary license from Merck that deliberately blocks many middle-income countries from producing and supplying this drug on their own. It is crystal clear that unless legal tools like the TRIPS waiver are adopted, many countries will continue to be at the mercy of patent-holding corporations that have the say over who gets to produce, who gets to buy, and at what price, while health ministries are already reeling from the rising costs of tackling COVID-19. We say to the remaining blocking governments: the eyes of the world are really just on you now—so you should think about what side of history you want to be on when the books on this pandemic are written.”

To end this pandemic for everyone, the US must alsoredistribute their excess vaccine doses to low- and middle-income countriesvia the COVAX Facility and regional procurement mechanisms, as well asdemand that Pfizer-BioNTech and Moderna share COVID-19 mRNA vaccine technologyand know-how so other able manufacturers can make additional mRNA vaccines and meet the global need.

Distributed by APO Group on behalf of Médecins sans frontières (MSF).